康希诺生物2025年度报告

2025 279 480 782 2783 34167 53 74 Xuefeng YU Xuefeng YUShou Bai CHAO (FCG HKFCG (PE)) 185401–420 33191901 H 183171712–1716 Xuefeng YU 1526 Xuefeng YU 77334 •8835 6185688185 www.cansinotech.com 20252025 20251,059.428.4%27.9 2022®®2025967.721.9%®3~683®7–59 ––13CRM197/TT®®®20 6 1,900II I 2026124 ®13PIC/S GMPGMPPIC/S (PQ) 2025ESG2025ESG2025 3(i)®®®Ad5–EBOVPBPVDTcP–Hib–MCV4PCV24(ii)®®®DTcPTdcp(iii)CS–2606 mRNACS–2023 • ®® ®NDAMCV4® ®IIIMCV2®3623 20211220216®®NDA20262®®MCV4®MPSV4®3683 ® ®967.721.9% 202412MCV4MCV41855MCV4 20252MCV4(LPPOM MUI)MCV4 20262MCV433473683 ®759 ® ®T2B 20256®NDA®NDA ®®® ®20 ®®®XBB.1.5 ®5SCOVID–19 ®®®®®®®®® 20212®NDANDA 20229®® 202312XBB.1.5XBB.1.5 Ad5–EBOV Ad5–EBOV50% 201710Ad5–EBOVNDAAd5–EBOVGMP Ad5–EBOV(i)2º C8º C12(ii)(iii) Ad5–EBOVAd5–EBOV DTcP DTcP(DTaP)DTcP DTcPDTcPTdcpDTcP 202412DTcPNDA 20252DTcPNDANDAsDTcPNDADTcP2026NDA 20252NDA2026NDA 20253 Tdcp Tdcp6 TdcpBoostrixAdacel 202412TdcpII/IIITdcpIIINDA • 20241I 202412I/IIIII/II 20257 PBPV PBPV23(PPV23)13(PCV13)2390PBPVAPspAPBPVPPV23PCV13 20244PBPVIIaIbIaIbPBPVIPBPV 20237Barinthus Biotherapeutics (UK) LimitedVaccitech (UK) LimitedShingrixShingrix 202311II I Ad5Ag85AIaI Ib 20255II1849 202511I DTcP–Hib–MCV4 DTcP–Hib–MCV4MCV4®DTcPIIIHibIDTcP–Hib–MCV4 20252DTcP–Hib–MCV4 202512DTcP–Hib–MCV4I PCV24 PCV2426242424 202612026PCV24I • mRNA mRNACMC(Chemistry, Manufacturing and Controls)mRNAmRNA 20247(NIBM)mRNAmRNA 20256(ISL)ISL–3C–LNPISLISL–3C–LNP 202511ISL–3C–LNPmRNAISL–3C–LNPLNPmRNAPRBT001mRNA ®®®mRNAmRNA A ®MCV4MCV®®®®® (COC)®®® 202512311,059.42024824.9®16.8 20251231260.120241231244.415.76.4%(i)(ii) 20251231799.320241231580.5218.8 20241231109.552.0%20251231166.4 20251231416.712.9%28.4% 20241231194.410.9%20251231173.1 20241231416.124.8%20251231313.0 2024123181.9202512314.6(1)70.5(2)4.50.5(3)6.3 – 2025123122.52024123122.244.7(1)18.517.4(2)29.1(3)21.4 202512316.120242.5 20241231180.120251231224.5III 20241231280.520251231338.320241231439.720251231361.5 20241231737.620251231782.9 20241231113.72025123190.919.411.2 2024123162.52025123150.4202512 31 20241231632.35.2%20251231599.4(i)(ii) 2024123175.12025123153.0 202412311,556.521.6%202512311,219.7 202512313,838.8202412314,282.51,219.7988.41,630.7 202512311,082.5202412311,772.0318.5599.4164.6 20251231318.520241231892.2956.9202412311,098.5MCV4 20251231988.0 202512312,244.7898.7 202433ª Vara Civel de Maringa/PRBelcher Farmaceutica Ltda.Belcher2021COVID–19167213 BelcherBelcher20251231 20251231 2025123118.820241231129.285.5% 2025123120251231149.020241231158.9 20251231 20251231 (i)(ii)2025123115.0104.812 3100%202512311.12%202412318.14% Xuefeng YU19636Yu20092009YuYu198571988619986(McGill)Yu30Yu1998–Sanofi Pasteur Limited–Yu19961998IBEX Technologies Inc.20244IBTYuAerasAeras Global TBVaccine FoundationAd5–EBOVAd5–nCoVYu10YuYu202072552 Shou Bai CHAO196282018ChaoChao1982719857199210Chao30ChaoGMP2011(ISPE)ChaoChaoCOVID–19ChaoChaoCOVID–19COVID–19 王 靖19801220212021202020212017202120201274320192020A+H 李 志 成19575202420241202412CSL Behring Asia Pacific Limited20222024201520222012201520062011Cephalon Inc.199720058Merck1996Abbott Laboratories Taiwan Limited19801995 202511Aulis Capital20251Stratation ConsultantsLimited20246Cognitact Limited2022TE Healthcare Advisory PteLtd2022202420202022212620152023CSL Behring Asia Pacific Limited20132015 2012201519801119869200610 張 耀 樑195910202423019861020151202012 2023255220241548202552021ADAG 20202024212620182020201320182011201320102011200920102006 1982619838 左 敏1961520251130 20241099662025700279320257 201362023626076016072017820238202082023820219202482020920249 紀 雪 峰1978520251110 2024112024620246126520231020233 20191201912•20162018(PPP) 2001620046 朱 濤19732200912024220091199571998620034(University ofPittsburgh)200410(Carnegie Mellon University)20042005Integrated Genomics Inc.20062008Ad5–EBOVCOVID–19COVID–19 Dongxu QIU19601Qiu2009120242Qiu2009120211QiuQiu1982719871219891119914(University of Konstanz)1992519931(University of Montreal)Qiu200010(University of Western Ontario)QiuQiu19931998Biomira, Inc.19992000Altarex Inc.20002002ARIUS Research Inc.20032005MDS Capital2006200920072011ChinaBioLLCQiuPCV13PPV23AHQiuIII 崔 進19873202192018201920162017201820182021201520162012201520096201112 崔 進1987320193 趙 明 璟1977220193VistraCorporate Services (HK) Limited202003201592020202519996200311 20251127 C1 C.2.135 C3 Xuefeng YUShou Bai CHAO 2025112720251127 2733 202511272025(i)(ii)(iii)(i)(ii)(i)(ii)(i)(ii)(iii) C.2.1HYuYu (i)(ii)Yu(iii) C.2.1 Xuefeng YUShou Bai CHAO 202511193.09D 3.21C1 (1)202511272025102720251127 (2)202511 27202511 27 • •2025•••••• 3.25C1 (1)202511272025102720251127(2)20251127(i)(ii)20251127 • 2025H2025A 42 20251231 1,500,0001,500,001- 2,000,0002,000,001- 2,500,0002,500,001- 3,000,0003,000,001- 3,500,000 C1 1127(i)(ii)2025102720251127 (2)20251127(i)(ii)20251127 •••• 731325 47.5%52.5% •(i)73(ii) • • • A